delegate
发表于 2025-3-25 06:18:46
http://reply.papertrans.cn/31/3008/300797/300797_21.png
宣称
发表于 2025-3-25 09:05:17
http://reply.papertrans.cn/31/3008/300797/300797_22.png
Ingenuity
发表于 2025-3-25 12:16:50
https://doi.org/10.1007/978-3-642-92213-8ting genomically targeted therapies with immune checkpoint inhibitors, such as monoclonal antibodies targeting cytotoxic T-lymphocyte associated antigen 4, programmed cell death protein 1, and PD-1 ligand 1, as well as the clinical status of key combination trials.
grotto
发表于 2025-3-25 18:33:24
Primer on Cancer Immunotherapy and the Targeting of Native Proteins,sient cellular interfaces. Methods for evaluating the presence and function of native proteins for therapeutic targeting necessitates resolving for tumor–immune cellular interactions to understand which cell type is expressing which native protein isoform in the contextual (variably inflamed) tumor
Alopecia-Areata
发表于 2025-3-25 21:08:15
http://reply.papertrans.cn/31/3008/300797/300797_25.png
熟练
发表于 2025-3-26 00:15:28
Cellular Therapy,lls have been used most successfully to treat patients with acute myelogenous leukemia. However, many trials and strategies are being developed to engineer NK cells to better target solid tumors. For cell-based therapies to gain widespread clinical utility, optimization of their manufacturing, admin
Ingrained
发表于 2025-3-26 06:57:06
Combinatorial Checkpoint Blockade Immunotherapy and Radiation, details of the abscopal effect and demonstrate the clinical efficacy of combined RT and CBI in treating cancer in both the definitive and metastatic setting. Here we review select preclinical and clinical data on radiation checkpoint blockade combinations.
dowagers-hump
发表于 2025-3-26 11:53:33
Immune Checkpoint Combinations with Inflammatory Pathway Modulators,exert downstream effects on immunosuppressive elements such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) which inhibit the function of effector T cells, NK cells, and dendritic cells, promoting immune tolerance and tumor growth. We herein review three targets for inflam
Efflorescent
发表于 2025-3-26 13:22:33
Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials,ting genomically targeted therapies with immune checkpoint inhibitors, such as monoclonal antibodies targeting cytotoxic T-lymphocyte associated antigen 4, programmed cell death protein 1, and PD-1 ligand 1, as well as the clinical status of key combination trials.
Bother
发表于 2025-3-26 20:08:52
http://reply.papertrans.cn/31/3008/300797/300797_30.png